Leinco Technologies

Anti-Human RANKL

Product Code:
 
LEI-R1242
Product Group:
 
Primary Antibodies
Host Type:
 
Rabbit
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-R1242-20ug20 ug£199.00
Quantity:
LEI-R1242-0.1mg0.1 mg£591.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:R1243
Long Description:
RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.1 RANKL is essential for osteoclast formation, activation, and survival.2 RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.3 RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.4
Target:
Receptor Activator of NF-κB Ligand

References

1. Takayanagi, H. et al. (2003) Arthritis Res Ther. 5: 20 2. Kostenuik, PJ. et al. (2005) Endocrinology 146: 3235 3. Holven, KB. et al. (2009) Stroke 40: 241 4. Penninger, JM. et al. (2008) Ann N Y Acad Sci. 1143: 123